Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Long-Term Survival of Patients with Relapsed/Refractory Acute Leukemia Receiving Clofarabine/Cyclophosphamide Prior to Hematopoietic Stem Cell Transplantation

Irene Graf, Philipp Wohlfarth, Margit Mitterbauer, Axel Schulenburg, Alexander Hauswirth, Karoline V. Gleixner, Werner Rabitsch, Peter Valent, Wolfgang R. Sperr

Blood (2024) 144 (Supplement 1): 5954.

https://doi.org/10.1182/blood-2024-206852

Published: 2024

Journal Articles

Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial

Blood (2024) 144 (Supplement 1): 3207.

https://doi.org/10.1182/blood-2024-208432

Published: 2024

Journal Articles

Tumor necrosis factor α promotes clonal dominance of KIT D816V + cells in mastocytosis: role of survivin and impact on prognosis

Blood (2024) 143 (11): 1006–1017.

https://doi.org/10.1182/blood.2023020515

Published: 2024

Includes: Supplemental data

Journal Articles

Delineation of Predictive Features of AML Patients with Recurrent Relapse Who Achieved Repeated Complete Remission after Multiple Re-Induction and Consolidation Therapies

Irene Graf, Georg Greiner, Karoline V. Gleixner, Susanne Herndlhofer, Gabriele Stefanzl, Paul Knöbl, Alexander Hauswirth, Manja Meggendorfer, Ulrich Jaeger, Constance Baer, Torsten Haferlach, Gregor Hoermann, Peter Valent, Wolfgang R. Sperr

Blood (2022) 140 (Supplement 1): 11634–11635.

https://doi.org/10.1182/blood-2022-162588

Published: 2022

Journal Articles

NT-Probnp As Personalized Medicine Tool and New Biomarker Predicting Response to Chemotherapy and Survival in AML

Irene Graf, Georg Greiner, Rodrig Marculescu, Karoline V. Gleixner, Susanne Herndlhofer, Gabriele Stefanzl, Paul Knoebl, Ulrich Jaeger, Alexander Hauswirth, Ilse Schwarzinger, Renate Thalhammer, Michael Kundi, Gregor Hoermann, Gerlinde Mitterbauer-Hohendanner, Peter Valent, Wolfgang R. Sperr

Blood (2021) 138 (Supplement 1): 3435.

https://doi.org/10.1182/blood-2021-149526

Published: 2021

Journal Articles

Deciphering the Mechanisms of Osteoblast-Induced Resistance of Leukemic Stem Cell (LSC) in Ph+ CML: Role of PI3-Kinase, BRD4 and MYC and Development of Strategies to Overcome Osteoblast-Induced Resistance

Yueksel Filik, Karin Bauer, Barbara Peter, Emir Hadzijusufovic, Georg Greiner, Nadine Witzeneder, Gregor Hoermann, Karoline V. Gleixner, Wolfgang R. Sperr, Peter Valent

Blood (2021) 138 (Supplement 1): 1481.

https://doi.org/10.1182/blood-2021-152415

Published: 2021

Journal Articles

Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis

Blood (2021) 137 (15): 2070–2084.

https://doi.org/10.1182/blood.2019004509

Published: 2021

Includes: Supplemental data

Journal Articles

Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis

Blood (2021) 137 (2): 238–247.

https://doi.org/10.1182/blood.2020006157

Published: 2021

Includes: Supplemental data

Journal Articles

Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML)

Gregor Eisenwort, MD PhD, Alexandra Keller, Michael Willmann, Irina Sadovnik, Greiner Georg, MD PhD, Karoline V. Gleixner, MD, Daniel Ivanov, MSc, Daniela Berger, Gabriele Stefanzl, Christiana Winding, DVM, Gregor Hoermann, Wolfgang R. Sperr, MD, Heinz Sill, MD, Peter Bettelheim, MD, Klaus Geissler, MD, Michael W. Deininger, Thomas Rülicke, Peter Valent, MD

Blood (2019) 134 (Supplement_1): 4223.

https://doi.org/10.1182/blood-2019-122530

Published: 2019

Journal Articles

Treatment of Patients with Aggressive Systemic Mastocytosis, Mast Cell Leukemia and Mast Cell Sarcoma: A Single Center Experience

Karoline V. Gleixner, MD, Peter Valent, Wolfgang R. Sperr

Blood (2018) 132 (Supplement 1): 1769.

https://doi.org/10.1182/blood-2018-99-116465

Published: 2018

Journal Articles

Emicizumab for the Treatment of Acquired Hemophilia_A: Lessons Learned from 4 Very Different Cases

Paul Knoebl, MD, Wolfgang R. Sperr, Peter Schellongowski, MD, Thomas Staudinger, MD, Petra Jilma-Stohlawetz, MD, Peter Quehenberger, MD, Silvia Koder, Ing, Cihan Ay, MD, Karoline V. Gleixner, MD

Blood (2018) 132 (Supplement 1): 2476.

https://doi.org/10.1182/blood-2018-99-116973

Published: 2018

Journal Articles

The CDK4/6 Inhibitor Palbociclib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest

Mathias A. Schneeweiss, Gabriele Stefanzl, Daniela Berger, Gregor Eisenwort, Mohamad Jawhar, Greiner Georg, MD PhD, Gregor Hoermann, Wolfgang R. Sperr, Michel Arock, Andreas Reiter, MD, Peter Valent, Karoline V. Gleixner, MD

Blood (2018) 132 (Supplement 1): 1363.

https://doi.org/10.1182/blood-2018-99-116525

Published: 2018

Journal Articles

Combined Targeting of STAT3 and STAT5: A Novel Approach to Overcome Drug Resistance in Ph + Cml

Karoline V Gleixner, MD, Mathias A Schneeweiss, MD, Harald Herrmann, MD, Katharina Blatt, MSc, PhD, Daniela Berger, Gregor Eisenwort, MD PhD, Georg Greiner, MD, Konstantin Byrgazov, PhD, Gregor Hoermann, Marina Konopleva, MD PhD, Islam Waliul, Patrick T Gunning, PhD, Hiroshi Maeda, PhD, Richard Moriggl, PhD, Michael W. Deininger, MD PhD, Thomas Lion, PhD, Michael Andreeff, MD PhD, Peter Valent, MD

Blood (2016) 128 (22): 4241.

https://doi.org/10.1182/blood.V128.22.4241.4241

Published: 2016

Journal Articles

Intensive Post-Remission Consolidation with G-CSF-Support: Tolerability, Safety, Reduced Hospitalization, and Efficacy of a New Treatment Protocol for AML Patients ≥60 Years

Wolfgang R. Sperr, MD, Susanne Herndlhofer, Karoline V Gleixner, MD, Michael Girschikofsky, MD, Ansgar Weltermann, MD, Sigrid Machherndl-Spandl, MD, Thamer Sliwa, MD, Rainer Poehnl, MD, Buxhofer-Ausch Veronika, MD, Karin Strecker, MD, Paul Knoebl, MD, Ulrich Jaeger, Klaus Geissler, MD, Michael Kundi, MD, Peter Valent, MD

Blood (2016) 128 (22): 2797.

https://doi.org/10.1182/blood.V128.22.2797.2797

Published: 2016

Journal Articles

Prognostic Factors and Survival Prediction in 1,088 Patients with Mastocytosis Collected in the Registry of the European Competence Network on Mastocytosis (ECNM Registry)

Blood (2016) 128 (22): 396.

https://doi.org/10.1182/blood.V128.22.396.396

Published: 2016

Journal Articles

The Multi-Kinase Inhibitor DCC-2618 Inhibits Proliferation and Survival of Neoplastic Mast Cells and Other Cell Types Involved in Systemic Mastocytosis

Mathias A Schneeweiss, MD, Barbara Peter, DVM, Katharina Blatt, MSc,PhD, Daniela Berger, Gabriele Stefanzl, Emir Hadzijusufovic, DVM, Karoline V Gleixner, MD, Peter Valent, MD

Blood (2016) 128 (22): 1965.

https://doi.org/10.1182/blood.V128.22.1965.1965

Published: 2016

Journal Articles

Hydroxyurea Induces Growth Inhibition in BCR-ABL1 T315I+ Clones and Synergizes with Ponatinib in Killing TKI-Resistant CML Cells

Mathias A Schneeweiss, MD, Konstantin Byrgazov, PhD, Chantal B Lucini, PhD, Susanne Herndlhofer, Wolfgang R. Sperr, MD, Thomas Lion, PhD, Gregor Hoermann, Michael W. Deininger, MD PhD, Peter Valent, MD, Karoline V Gleixner, MD

Blood (2016) 128 (22): 5425.

https://doi.org/10.1182/blood.V128.22.5425.5425

Published: 2016

Journal Articles

Maintenance with Histamine and IL-2 Induces a Marked Expansion of Activated CD56 bright NK Cells in Acute Myeloid Leukemia

Angelica Cuapio, Dr. MD, Mirte Post, Sabine Cerny-Reiterer, Dr., Markus Osl, Volker Huppert, PhD, Karoline V Gleixner, MD, Susanne Herndlhofer, Wolfgang R Sperr, MD, Peter Valent, MD, Erhard Hofer, Dr.

Blood (2014) 124 (21): 1422.

https://doi.org/10.1182/blood.V124.21.1422.1422

Published: 2014

Journal Articles

KIT D816V Mutation Burden Predicts Prognosis and Survival In Patients With Mastocytosis and Correlates With The WHO Type Of The Disease

Gregor Hoermann, M.D., Ph.D., Karoline V. Gleixner, M.D., Graziella E. Dinu, B.Sc., Georg Greiner, Friedrich Wimazal, M.D., Emir Hadzijusufovic, DVM, Gerlinde Mitterbauer, M.D., Christine Mannhalter, Ph.D., Peter Valent, Wolfgang R Sperr, M.D.

Blood (2013) 122 (21): 4052.

https://doi.org/10.1182/blood.V122.21.4052.4052

Published: 2013

Journal Articles

Small-Molecule Inhibition of BRD4 Is a Novel Promising Approach to Therapeutically Target Leukemia Stem Cells in AML,

Harald Herrmann, M.D., Katharina Blatt, M.Sc., Junwei Shi, Amy R. Rappaport, Karoline V. Gleixner, M.D., Sabine Cerny-Reiterer, D.V.M., Barbara Peter, D.V.M., Eric Wang, Wolfgang R. Sperr, M.D., James E. Bradner, MD, Scott W. Lowe, Ph.D., Christopher R. Vakoc, M.D., Ph.D., Johannes Zuber, M.D., Peter Valent, M.D.

Blood (2011) 118 (21): 3484.

https://doi.org/10.1182/blood.V118.21.3484.3484

Published: 2011

NARROW

Long-Term Survival of Patients with Relapsed/Refractory Acute Leukemia Receiving Clofarabine/Cyclophosphamide Prior to Hematopoietic Stem Cell Transplantation

Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial

Tumor necrosis factor α promotes clonal dominance of KIT D816V + cells in mastocytosis: role of survivin and impact on prognosis

Delineation of Predictive Features of AML Patients with Recurrent Relapse Who Achieved Repeated Complete Remission after Multiple Re-Induction and Consolidation Therapies

NT-Probnp As Personalized Medicine Tool and New Biomarker Predicting Response to Chemotherapy and Survival in AML

Deciphering the Mechanisms of Osteoblast-Induced Resistance of Leukemic Stem Cell (LSC) in Ph+ CML: Role of PI3-Kinase, BRD4 and MYC and Development of Strategies to Overcome Osteoblast-Induced Resistance

Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis

Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis

Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML)

Treatment of Patients with Aggressive Systemic Mastocytosis, Mast Cell Leukemia and Mast Cell Sarcoma: A Single Center Experience

Emicizumab for the Treatment of Acquired Hemophilia_A: Lessons Learned from 4 Very Different Cases

The CDK4/6 Inhibitor Palbociclib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest

Combined Targeting of STAT3 and STAT5: A Novel Approach to Overcome Drug Resistance in Ph + Cml

Intensive Post-Remission Consolidation with G-CSF-Support: Tolerability, Safety, Reduced Hospitalization, and Efficacy of a New Treatment Protocol for AML Patients ≥60 Years

Prognostic Factors and Survival Prediction in 1,088 Patients with Mastocytosis Collected in the Registry of the European Competence Network on Mastocytosis (ECNM Registry)

The Multi-Kinase Inhibitor DCC-2618 Inhibits Proliferation and Survival of Neoplastic Mast Cells and Other Cell Types Involved in Systemic Mastocytosis

Hydroxyurea Induces Growth Inhibition in BCR-ABL1 T315I+ Clones and Synergizes with Ponatinib in Killing TKI-Resistant CML Cells

Maintenance with Histamine and IL-2 Induces a Marked Expansion of Activated CD56 bright NK Cells in Acute Myeloid Leukemia

KIT D816V Mutation Burden Predicts Prognosis and Survival In Patients With Mastocytosis and Correlates With The WHO Type Of The Disease

Small-Molecule Inhibition of BRD4 Is a Novel Promising Approach to Therapeutically Target Leukemia Stem Cells in AML,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only